Over 3 Million EU Pigs Get the CIRCOVAC Treatment SOUTH AFRICA - MERIAL's CIRCOVAC® obtained its European Registration from the E.M.E.A. exactly one year ago on the 21st of June 2007 which meant that MERIAL could launch CIRCOVAC® in all EU Member States. Since then CIRCOVAC® has also obtained its full license in many other non-EU countries such as Switzerland, Brazil, Colombia, Costa Rica, Panama, Thailand, Japan.

During this 20th IPVS congress in Durban, MERIAL is presenting new data confirming the huge benefits experienced in Germany, France, Denmark, the UK, Canada and Japan further to the vaccination of herds with CIRCOVAC®:

• Denmark: CIRCOVAC® induces a significant decrease in mortality attributable to PCV2 diseases and crude mortality.
  After vaccination with CIRCOVAC® in 5 Danish finishing farms, mortality went from 7% before vaccination to 4% (close to the National Danish reference figure).
  
  
• France: CIRCOVAC® optimizes growth performance.
  A comparison of the technico/economic data (GTE) before and after CIRCOVAC® vaccination in 13 French farms showed a significant improvement in the weaning-to-slaughter period (5 days less) and of the ADWG by +38g per day from 8 to 115 kg.
  
  
• Germany: CIRCOVAC® improves growth reproduction parameters.
  Both fertility and prolificity parameters were positively impacted after vaccination of sows with CIRCOVAC®: in 277 farms in Germany the number of weaned piglets per sow per year went up significantly by 1.13.
  
  
• Denmark and UK: CIRCOVAC® restores profitability.
  CIRCOVAC® was found to decrease the frequency of use of medication, especially anti-infectives. A Danish indicator used to evaluate the antibiotic consumption per animal per day (ADD%) demonstrated a significant drop in many farms after the vaccination of sows with CIRCOVAC®. In one farm in the UK, the cost of medication per fattening pig decreased from £0.33 to £0.03.
  
  Huge economic benefits in all countries using CIRCOVAC® vaccine: Four years of unrivalled field experience in several different countries have more than confirmed the economic benefits of CIRCOVAC® vaccination: between €80 and €120 per sow per year (taking into account the technico/economic performance of the pigs) and around €74 (improvement of the reproductive parameters), which means an overall improvement of around €194 per sow per year.

CIRCOVAC® is an inactivated vaccine against Porcine Circovirus type 2 (PCV2), to be administered to sows and gilts. Newborn piglets with good colostrum uptake can take full advantage of highly effective and specific passive protection against PCV2 infection. The vaccination of sows and gilts with CIRCOVAC® helps the immune system of their piglets so that they can mature in a correct and efficient way during the first weeks of life. Subsequently, piglets born to vaccinated sows will be able to develop their own active immunity against PCV2.

CIRCOVAC® is injected via the intramuscular route as follows:

• Gilts/sows: one injection, followed 3 to 4 weeks later, by a second injection, at least 2 weeks before mating or farrowing, accordingly.
• Re-vaccination: one injection at each gestation, at least 2 to 4 weeks before farrowing.

With over 3 million sows already vaccinated to date, CIRCOVAC® has already achieved unmatched field results.

CIRCOVAC® is intended for use on farms with signs of PCV2 diseases and poor performance rates in pigs of varying ages. CIRCOVAC® brings back pig farm profitability and restores the farmer's peace of mind allowing him to focus on his main priority: raising healthy pigs.

For over 11 years, MERIAL has been a major player in the research of PMWS and PCV2-associated diseases. MERIAL's priority has been to offer a solution to the swine industry against a new and devastating syndrome. CIRCOVAC® is the biological answer.

Further Reading

-

Read all avout CIRCOVAC by clicking here.